A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes.
paper
Cited
Public
Unavailable
- Authors
- Messina, E S; Tyndale, R F; Sellers, E M
- Year
- 1997
- Journal
- The Journal of pharmacology and experimental therapeutics
- PMID
- 9316878
Nicotine is primarily metabolized to cotinine by cytochromes P450 (CYPs). The degree of variation in the metabolism of nicotine to cotinine and the relative roles of the polymorphic enzymes CYP2A6 and CYP2D6 in this metabolism were investigated. The apparent K(m) and V(max) values (mean +/- S.D.) for cotinine formation in human liver microsomes (n = 31) were 64.9 +/- 32.7 microM and 28.1 +/- 28.7 nmol/mg of protein/hr, respectively. A 30-fold difference was seen among the individual V(max) values, with four livers showing significantly higher rates of cotinine formation. CYP2D6 is unimportant in nicotine metabolism because quinidine (a CYP2D6 inhibitor) had little effect on inhibition of cotinine formation; V(max) values for dextromethorphan (CYP2D6 probe substrate) and nicotine (n = 9) did not correlate (r = .49, P = .18), and a cDNA CYP2D6 expression system failed to metabolize nicotine to cotinine. CYP2A6 appears to be the major P450 involved in human nicotine metabolism to cotinine. Coumarin, a specific and selective CYP2A6 substrate, competitively inhibited cotinine formation by 85 +/- 11% (mean +/- S.D.) in 31 human livers. The K(i) value for this inhibition ranged from 1 to 5 microM, and a CYP2A6 monoclonal antibody inhibited cotinine formation by >75%. Immunochemically determined CYP2A6 correlated significantly with nicotine-to-cotinine V(max) values (r = .90, n = 30, P < .001) and to inhibition of nicotine metabolism by coumarin (r = .94, n = 30, P < .001). These data indicate that nicotine metabolism is highly variable among individual livers and that this is due to variable expression of CYP2A6, not CYP2D6.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| A quantitative comparison of the deleteriousness of missense and nonsense mutations using the structurally resolved human protein interactome. | Su TY et al. | β | 2025 | β |
| Extending Investigations of miR-126-5p on the Regulation of CYP2A6, the Major Nicotine-Inactivating Enzyme. | Gu W et al. | β | 2025 | β |
| PharmVar GeneFocus: CYP2A6. | Langlois AWR et al. | β | 2024 | β |
| Biomarkers of exposure in urine of active smokers, non-smokers, and vapers. | Gallart-Mateu D et al. | β | 2023 | β |
| Design, Synthesis, and Biological Studies of Flavone-Based Esters and Acids as Potential P450 2A6 Inhibitors. | Goyal N et al. | β | 2023 | β |
| E-Cigarette Liquids and Aldehyde Flavoring Agents Inhibit CYP2A6 Activity in Lung Epithelial Cells. | Winters BR et al. | β | 2023 | β |
| Effects of Genetic Variants in the Nicotine Metabolism Pathway on Smoking Cessation. | Li H et al. | β | 2022 | β |
| Evaluation of the nicotine metabolite ratio in smoking patients treated with varenicline and bupropion. | Tomaz PRX et al. | β | 2022 | β |
| Review of HPLC-MS methods for the analysis of nicotine and its active metabolite cotinine in various biological matrices. | Jin S et al. | β | 2022 | β |
| Treatment outcomes in poor metabolizers of cytochrome P450 2A6 with concurrent chemoradiotherapy in locally advanced head- and neck-squamous cell carcinoma. | Aggarwal D et al. | β | 2022 | β |
| Acute effects of a very low nicotine content cigarette on laboratory smoking lapse: Impacts of nicotine metabolism and nicotine dependence. | Schlagintweit HE et al. | β | 2021 | β |
| Biochemistry of nicotine metabolism and its relevance to lung cancer. | Murphy SE | β | 2021 | β |
| Cytochrome P450 expression and regulation in the brain. | Kuban W et al. | β | 2021 | β |
| Metabolic activation of deferiprone mediated by CYP2A6. | Zheng X et al. | β | 2021 | β |
| PPARΞ± agonist WY-14,643 enhances ethanol metabolism in mice: Role of catalase. | Chen X et al. | β | 2021 | β |
| Changes in Nicotine Metabolite Ratio Among Daily Smokers Receiving Treatment for Alcohol Use Disorder. | Dermody SS et al. | β | 2020 | β |
| Cytochrome P450 2A6 whole-gene deletion (CYP2A6*4) polymorphism reduces risk of lung cancer: A meta-analysis. | Johani FH et al. | β | 2020 | β |
| Insight into the Interaction Mechanism of Nicotine, NNK, and NNN with Cytochrome P450 2A13 Based on Molecular Dynamics Simulation. | Neves Cruz J et al. | β | 2020 | β |
| Mechanisms of Herb-Drug Interactions Involving Cinnamon and CYP2A6: Focus on Time-Dependent Inhibition by Cinnamaldehyde and 2-Methoxycinnamaldehyde. | Espiritu MJ et al. | β | 2020 | β |
| Personalized dosing of nicotine replacement therapy versus standard dosing for the treatment of individuals with tobacco dependence: study protocol for a randomized placebo-controlled trial. | Zawertailo L et al. | β | 2020 | β |
| Pharmacogenomics of Nicotine Metabolism: Novel CYP2A6 and CYP2B6 Genetic Variation Patterns in Alaska Native and American Indian Populations. | Claw KG et al. | β | 2020 | β |
| Postnatal Smoke Exposure Further Increases the Hepatic Nicotine Metabolism in Prenatally Smoke Exposed Male Offspring and Is Linked with Aberrant <i>Cyp2a5</i> Methylation. | Lkhagvadorj K et al. | β | 2020 | β |
| Prenatal smoke exposure induces persistent <i>Cyp2a5</i> methylation and increases nicotine metabolism in the liver of neonatal and adult male offspring. | Lkhagvadorj K et al. | β | 2020 | β |
| The Biological Impact of Menthol on Tobacco Dependence. | Wickham RJ | β | 2020 | β |
| The Impact of Sex on Changes in Plasma Corticosterone and Cotinine Levels Induced by Nicotine in C57BL/6J Mice. | Nguyen K et al. | β | 2020 | β |
| Does the nicotine metabolite ratio moderate smoking cessation treatment outcomes in real-world settings? A prospective study. | Shahab L et al. | β | 2019 | β |
| Evaluating metronidazole as a novel, safe CYP2A6 phenotyping probe in healthy adults. | Stancil SL et al. | β | 2019 | β |
| Identification of diagnostic long nonβcoding RNA biomarkers in patients with hepatocellular carcinoma. | Li G et al. | β | 2019 | β |
| Pregnancy-Induced Increases in the Nicotine Metabolite Ratio: Examining Changes During Antepartum and Postpartum. | Arger CA et al. | β | 2019 | β |
| Suppressed hepatocyte proliferation via a ROS-HNE-P21 pathway is associated with nicotine- and cotinine-enhanced alcoholic fatty liver in mice. | Chen X et al. | β | 2019 | β |
| The neurobiology of addiction. | Uhl GR et al. | β | 2019 | β |
| A Comparison of Direct and Indirect Analytical Approaches to Measuring Total Nicotine Equivalents in Urine. | Taghavi T et al. | β | 2018 | β |
| A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways. | Dallmann A et al. | β | 2018 | β |
| Cigarette consumption and biomarkers of nicotine exposure during pregnancy and postpartum. | Taghavi T et al. | β | 2018 | β |
| Cytochrome P450s and Alcoholic Liver Disease. | Lu Y et al. | β | 2018 | β |
| Dermal uptake of nicotine from air and clothing: Experimental verification. | BekΓΆ G et al. | β | 2018 | β |
| From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation. | Salloum NC et al. | β | 2018 | β |
| Longitudinal Influence of Pregnancy on Nicotine Metabolic Pathways. | Taghavi T et al. | β | 2018 | β |
| Nicotine enhances alcoholic fatty liver in mice: Role of CYP2A5. | Chen X et al. | β | 2018 | β |
| Nicotine metabolite ratio predicts smoking topography: The Pennsylvania Adult Smoking Study. | Chen A et al. | β | 2018 | β |
| Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism. | Tanner JA et al. | β | 2018 | β |
| Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations. | MacParland SA et al. | β | 2018 | β |
| Understanding the implications of the biobehavioral basis of nicotine addiction and its impact on the efficacy of treatment. | Bozinoff N et al. | β | 2018 | β |
| Using Phytochemicals to Investigate the Activation of Nicotine Detoxification via Upregulation of CYP2A6 in Animal Models Exposed Tobacco Smoke Condensate by Intratracheal Instillation. | Lee D et al. | β | 2018 | β |
| A convenient UHPLC-MS/MS method for routine monitoring of plasma and brain levels of nicotine and cotinine as a tool to validate newly developed preclinical smoking model in mouse. | Kaisar MA et al. | β | 2017 | β |
| Characterising the nicotine metabolite ratio and its association with treatment choice: A cross sectional analysis of Stop Smoking Services in England. | Shahab L et al. | β | 2017 | β |
| Curcumin Successfully Inhibited the Computationally Identified CYP2A6 Enzyme-Mediated Bioactivation of Aflatoxin B1 in Arbor Acres broiler. | Muhammad I et al. | β | 2017 | β |
| CYP2A6 Genetic Variation Alters Striatal-Cingulate Circuits, Network Hubs, and Executive Processing in Smokers. | Li S et al. | β | 2017 | β |
| CYP2D6 and CYP2A6 biotransform dietary tyrosol into hydroxytyrosol. | RodrΓguez-MoratΓ³ J et al. | β | 2017 | β |
| Delivery of nicotine aerosol to mice via a modified electronic cigarette device. | Lefever TW et al. | β | 2017 | β |
| Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction. | LΓ³pez-Flores LA et al. | β | 2017 | β |
| Does menthol cigarette use moderate the effect of nicotine metabolism on short-term smoking cessation? | Jao NC et al. | β | 2017 | β |
| Modelling foetal exposure to maternal smoking using hepatoblasts from pluripotent stem cells. | Lucendo-Villarin B et al. | β | 2017 | β |
| Ortho-Methylarylamines as Time-Dependent Inhibitors of Cytochrome P450 1A1 Enzyme. | Sridhar J et al. | β | 2017 | β |
| Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors. | Tanner JA et al. | β | 2017 | β |
| Variation in CYP2A6 Activity and Personalized Medicine. | Tanner JA et al. | β | 2017 | β |
| Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer. | Tanner JA et al. | β | 2017 | β |
| Contribution of Monoamine Oxidase Inhibition to Tobacco Dependence: A Review of the Evidence. | Hogg RC | β | 2016 | β |
| Genomic Landscape of Experimental Bladder Cancer in Rodents and Its Application to Human Bladder Cancer: Gene Amplification and Potential Overexpression of Cyp2a5/CYP2A6 Are Associated with the Invasive Phenotype. | Kanemoto K et al. | β | 2016 | β |
| Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. | Chan J et al. | β | 2016 | β |
| Nicotine Metabolism in Young Adult Daily Menthol and Nonmenthol Smokers. | Fagan P et al. | β | 2016 | β |
| Nicotine Metabolite Ratio Is Associated With Lozenge Use But Not Quitting in Smokeless Tobacco Users. | Ebbert JO et al. | β | 2016 | β |
| Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio. | Allenby CE et al. | β | 2016 | β |
| Association of 5-HTTLPR polymorphism with smoking behaviors: A meta-analysis. | Li H et al. | β | 2015 | β |
| Association of CYP2A6 gene polymorphisms with cigarette consumption: a meta-analysis. | Pan L et al. | β | 2015 | β |
| Associations Between Genetic Ancestries and Nicotine Metabolism Biomarkers in the Multiethnic Cohort Study. | Wang H et al. | β | 2015 | β |
| Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date. | Mamoun M et al. | β | 2015 | β |
| Biomarkers of tobacco smoke exposure in racial/ethnic groups at high risk for lung cancer. | Fagan P et al. | β | 2015 | β |
| Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption. | Bergen AW et al. | β | 2015 | β |
| Effects of cigarette smoking and nicotine metabolite ratio on leukocyte telomere length. | Verde Z et al. | β | 2015 | β |
| Effects of Smoking on Arterial Stiffness in Male Adolescents in Lusaka, Zambia. | Theresa C et al. | β | 2015 | β |
| How Menthol Alters Tobacco-Smoking Behavior: A Biological Perspective. | Wickham RJ | β | 2015 | β |
| N-acetyltransferase 1 polymorphism increases cotinine levels in Caucasian children exposed to secondhand smoke: the CCAAPS birth cohort. | LeMasters GK et al. | β | 2015 | β |
| Nicotine metabolite ratio (3-hydroxycotinine/cotinine) in plasma and urine by different analytical methods and laboratories: implications for clinical implementation. | Tanner JA et al. | β | 2015 | β |
| Pharmacogenetics of nicotine and associated smoking behaviors. | Tanner JA et al. | β | 2015 | β |
| Smoking topography in Korean American and white men: preliminary findings. | Chung S et al. | β | 2015 | β |
| Test-Retest Reliability and Stability of the Nicotine Metabolite Ratio Among Treatment-Seeking Smokers. | Hamilton DA et al. | β | 2015 | β |
| The contribution of common genetic variation to nicotine and cotinine glucuronidation in multiple ethnic/racial populations. | Patel YM et al. | β | 2015 | β |
| Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice. | Bagdas D et al. | β | 2014 | β |
| Finding genomic function for genetic associations in nicotine addiction research: the ENCODE project's role in future pharmacogenomic analysis. | Vandenbergh DJ et al. | β | 2014 | β |
| Genetics and smoking. | Loukola A et al. | β | 2014 | β |
| Nicotine pharmacokinetics in rats is altered as a function of age, impacting the interpretation of animal model data. | Craig EL et al. | β | 2014 | β |
| Pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice: effects of methoxsalen, a CYP2A5/6 inhibitor. | Alsharari SD et al. | β | 2014 | β |
| Biomarkers for smoking cessation. | Bough KJ et al. | β | 2013 | β |
| Catalytic mechanism of cytochrome P450 for N-methylhydroxylation of nicotine: reaction pathways and regioselectivity of the enzymatic nicotine oxidation. | Li D et al. | β | 2013 | β |
| Cytochrome P450 2A isoenzymes in freshly prepared blood lymphocytes isolated from rats and validation as a biomarker for clinical studies in humans. | Sharma A et al. | β | 2013 | β |
| Detection of tobacco-related biomarkers in urine samples by surface-enhanced Raman spectroscopy coupled with thin-layer chromatography. | Huang R et al. | β | 2013 | β |
| Estimation of cutoff values of cotinine in urine and saliva for pregnant women in Poland. | Stragierowicz J et al. | β | 2013 | β |
| Feasibility of identifying the tobacco-related global metabolome in blood by UPLC-QTOF-MS. | Hsu PC et al. | β | 2013 | β |
| Nicotine kinetics in zebra finches in vivo and in vitro. | Miksys S et al. | β | 2013 | β |
| Nicotine metabolism and addiction among adolescent smokers. | Rubinstein ML et al. | β | 2013 | β |
| Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial. | Faseru B et al. | β | 2013 | β |
| Race, gender, and nicotine metabolism in adolescent smokers. | Rubinstein ML et al. | β | 2013 | β |
| Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake. | Zhu AZ et al. | β | 2013 | β |
| An LC-MS/MS method for concurrent determination of nicotine metabolites and the role of CYP2A6 in nicotine metabolite-mediated oxidative stress in SVGA astrocytes. | Ande A et al. | β | 2012 | β |
| Application of the buccal micronucleus cytome assay and analysis of PON1Gln192Arg and CYP2A6*9(-48T>G) polymorphisms in tobacco farmers. | Da Silva FR et al. | β | 2012 | β |
| CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people. | Binnington MJ et al. | β | 2012 | β |
| Differential effects of nicotine treatment and ethanol self-administration on CYP2A6, CYP2B6 and nicotine pharmacokinetics in African green monkeys. | Ferguson CS et al. | β | 2012 | β |
| Interplay between smoking-induced genotoxicity and altered signaling in pancreatic carcinogenesis. | Momi N et al. | β | 2012 | β |
| Nicotine, cotinine, and myosmine determination using polymer films of tailor-designed zinc porphyrins as recognition units for piezoelectric microgravimetry chemosensors. | Noworyta K et al. | β | 2012 | β |
| Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. | Gold AB et al. | β | 2012 | β |
| Positive and negative effects of alcohol and nicotine and their interactions: a mechanistic review. | Hurley LL et al. | β | 2012 | β |
| Reproducibility of the nicotine metabolite ratio in cigarette smokers. | St Helen G et al. | β | 2012 | β |
| The genetics of substance dependence. | Wang JC et al. | β | 2012 | β |
| Catalytic mechanism of cytochrome P450 for 5'-hydroxylation of nicotine: fundamental reaction pathways and stereoselectivity. | Li D et al. | β | 2011 | β |
| Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. | Khojasteh SC et al. | β | 2011 | β |
| Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. | Chuah B et al. | β | 2011 | β |
| Computational insights into the different catalytic activities of CYP2A13 and CYP2A6 on NNK. | Xu Y et al. | β | 2011 | β |
| Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data. | Cox LS et al. | β | 2011 | β |
| Determination of the nicotine metabolites cotinine and trans-3'-hydroxycotinine in biologic fluids of smokers and non-smokers using liquid chromatography-tandem mass spectrometry: biomarkers for tobacco smoke exposure and for phenotyping cytochrome P450 2A6 activity. | Jacob P et al. | β | 2011 | β |
| Genistein alters caffeine exposure in healthy female volunteers. | Chen Y et al. | β | 2011 | β |
| Identification of novel CYP2A6 inhibitors by virtual screening. | Rahnasto MK et al. | β | 2011 | β |
| Lack of promoting effects from physical pulmonary collapse in a female A/J mouse lung tumor initiated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) with remarkable mesothelial cell reactions in the thoracic cavity by the polymer. | Yokohira M et al. | β | 2011 | β |
| Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. | Strasser AA et al. | β | 2011 | β |
| Pharmacogenetics of alcohol, nicotine and drug addiction treatments. | Sturgess JE et al. | β | 2011 | β |
| Systematic review of the relationship between the 3-hydroxycotinine/cotinine ratio and cigarette dependence. | West O et al. | β | 2011 | β |
| Treatment for tobacco dependence: a potential application for stratified medicine? | Brock AJ et al. | β | 2011 | β |
| Expression and characterization of dog cytochrome P450 2A13 and 2A25 in baculovirus-infected insect cells. | Zhou D et al. | β | 2010 | β |
| Fundamental reaction pathways for cytochrome P450-catalyzed 5'-hydroxylation and N-demethylation of nicotine. | Li D et al. | β | 2010 | β |
| Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors. | Al Koudsi N et al. | β | 2010 | β |
| Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism. | Al Koudsi N et al. | β | 2010 | β |
| Liu wei di huang wan, a well-known traditional Chinese medicine, induces CYP1A2 while suppressing CYP2A6 and N-acetyltransferase 2 activities in man. | Chen Y et al. | β | 2010 | β |
| New CYP2A6 gene deletion and conversion variants in a population of Black African descent. | Mwenifumbo JC et al. | β | 2010 | β |
| Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. | Mroziewicz M et al. | β | 2010 | β |
| Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment. | Khokhar JY et al. | β | 2010 | β |
| Pharmacogenetics of smoking cessation therapy. | Kortmann GL et al. | β | 2010 | β |
| Plant polyphenol curcumin significantly affects CYP1A2 and CYP2A6 activity in healthy, male Chinese volunteers. | Chen Y et al. | β | 2010 | β |
| Role of CYP2A5 in the clearance of nicotine and cotinine: insights from studies on a Cyp2a5-null mouse model. | Zhou X et al. | β | 2010 | β |
| A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. | Al Koudsi N et al. | β | 2009 | β |
| Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. | Ho MK et al. | β | 2009 | β |
| Coffee intake, variants in genes involved in caffeine metabolism, and the risk of epithelial ovarian cancer. | Kotsopoulos J et al. | β | 2009 | β |
| Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity. | Neafsey P et al. | β | 2009 | β |
| Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases? | Quaak M et al. | β | 2009 | β |
| Implications of gene-drug interactions in smoking cessation for improving the prevention of chronic degenerative diseases. | Quaak M et al. | β | 2009 | β |
| Lack of Modifying Effects of Intratracheal Instillation of Quartz or Dextran Sulfate Sodium (DSS) in Drinking Water on Lung Tumor Development Initiated with 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in Female A/J Mice. | Yokohira M et al. | β | 2009 | β |
| Mechanism-based medication development for the treatment of nicotine dependence. | Xi ZX et al. | β | 2009 | β |
| Nicotine chemistry, metabolism, kinetics and biomarkers. | Benowitz NL et al. | β | 2009 | β |
| Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. | Ray R et al. | β | 2009 | β |
| Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. | Schnoll RA et al. | β | 2009 | β |
| Polymorphism of human cytochrome P450 enzymes and its clinical impact. | Zhou SF et al. | β | 2009 | β |
| Utility and relationships of biomarkers of smoking in African-American light smokers. | Ho MK et al. | β | 2009 | β |
| A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. | Ho MK et al. | β | 2008 | β |
| CYP2A6 polymorphisms and risk for tobacco-related cancers. | Rossini A et al. | β | 2008 | β |
| Establishment of a bioassay model for lung cancer chemoprevention initiated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in female A/J mice. | Yokohira M et al. | β | 2008 | β |
| Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. | Mwenifumbo JC et al. | β | 2008 | β |
| Inhibition and induction of human cytochrome P450 enzymes: current status. | Pelkonen O et al. | β | 2008 | β |
| Nicotine metabolism and urinary elimination in mouse: in vitro and in vivo. | Raunio H et al. | β | 2008 | β |
| Nicotinic receptors containing the alpha7 subunit: a model for rational drug design. | Sharma G et al. | β | 2008 | β |
| Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. | Mwenifumbo JC et al. | β | 2008 | β |
| Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. | Buchhalter AR et al. | β | 2008 | β |
| Rate of nicotine metabolism and withdrawal symptoms in adolescent light smokers. | Rubinstein ML et al. | β | 2008 | β |
| Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. | Siu EC et al. | β | 2008 | β |
| Socioeconomic and drug use determinants of smoking status in an urban adult population of Black African descent. | Mwenifumbo JC et al. | β | 2008 | β |
| The ontogeny of drug metabolism enzymes and implications for adverse drug events. | Hines RN | β | 2008 | β |
| Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. | Patterson F et al. | β | 2008 | β |
| A biopsychosocial approach to examining tobacco-related health disparities among racially classified social groups. | Fernander AF et al. | β | 2007 | β |
| Alterations in drug disposition during pregnancy: implications for drug therapy. | Hodge LS et al. | β | 2007 | β |
| Application of nicotine enantiomers, derivatives and analogues in therapy of neurodegenerative disorders. | Pogocki D et al. | β | 2007 | β |
| CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. | Lee AM et al. | β | 2007 | β |
| CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy. | Lee AM et al. | β | 2007 | β |
| Expression, microsomal and mitochondrial activities of cytochrome P450 enzymes in brain regions from control and phenobarbital-treated rabbits. | Marini S et al. | β | 2007 | β |
| Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism. | Ring HZ et al. | β | 2007 | β |
| Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. | Mwenifumbo JC et al. | β | 2007 | β |
| Inhibition of nicotine metabolism by methoxysalen: Pharmacokinetic and pharmacological studies in mice. | Damaj MI et al. | β | 2007 | β |
| In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. | Begas E et al. | β | 2007 | β |
| Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking. | Mwenifumbo JC et al. | β | 2007 | β |
| Overview of the pharmacogenomics of cigarette smoking. | Ho MK et al. | β | 2007 | β |
| Pharmacogenetics and smoking cessation with nicotine replacement therapy. | Ray R et al. | β | 2007 | β |
| Pharmacological approaches to smoking cessation. | Mitrouska I et al. | β | 2007 | β |
| The role of CYP2A6 in the emergence of nicotine dependence in adolescents. | Audrain-McGovern J et al. | β | 2007 | β |
| Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. | Al Koudsi N et al. | β | 2006 | β |
| CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. | Nakajima M et al. | β | 2006 | β |
| Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. | Malaiyandi V et al. | β | 2006 | β |
| Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism. | von Weymarn LB et al. | β | 2006 | β |
| Liver enzyme induction and inhibition: implications for anaesthesia. | Sweeney BP et al. | β | 2006 | β |
| Monoamine oxidase A rather than monoamine oxidase B inhibition increases nicotine reinforcement in rats. | Guillem K et al. | β | 2006 | β |
| Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. | Siu EC et al. | β | 2006 | β |
| Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein. | Lee AM et al. | β | 2006 | β |
| Prenatal cigarette smoke exposure: pregnancy outcome and gestational changes in plasma nicotine concentration, hematocrit, and carboxyhemoglobin in a newly standardized rat model. | Farkas S et al. | β | 2006 | β |
| Risk factors for tobacco dependence in adolescent smokers. | Karp I et al. | β | 2006 | β |
| Tailoring nicotine replacement therapy: rationale and potential approaches. | McClure JB et al. | β | 2006 | β |
| The genetics of nicotine dependence: relationship to pancreatic cancer. | MacLeod SL et al. | β | 2006 | β |
| Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. | Anderson GD | β | 2006 | β |
| Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort. | Gambier N et al. | β | 2005 | β |
| Brain uptake kinetics of nicotine and cotinine after chronic nicotine exposure. | Lockman PR et al. | β | 2005 | β |
| Chronic nicotine exposure alters blood-brain barrier permeability and diminishes brain uptake of methyllycaconitine. | Lockman PR et al. | β | 2005 | β |
| CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians. | Vasconcelos GM et al. | β | 2005 | β |
| Dispositional motivations and genetic risk feedback. | Westmaas JL et al. | β | 2005 | β |
| Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. | Mwenifumbo JC et al. | β | 2005 | β |
| Generation and characterization of a transgenic mouse model with hepatic expression of human CYP2A6. | Zhang QY et al. | β | 2005 | β |
| Genetic influences on smoking: a brief review. | Al Koudsi N et al. | β | 2005 | β |
| Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. | Malaiyandi V et al. | β | 2005 | β |
| Inter-gene correlation on oligonucleotide arrays: how much does normalization matter? | Gold DL et al. | β | 2005 | β |
| [Markers of environmental tobacco smoke (ETS) exposure]. | Metz-Favre C et al. | β | 2005 | β |
| Metabolism and disposition kinetics of nicotine. | Hukkanen J et al. | β | 2005 | β |
| Metabolism of nicotine and cotinine by human cytochrome P450 2A13. | Bao Z et al. | β | 2005 | β |
| Nicotine 5'-oxidation and methyl oxidation by P450 2A enzymes. | Murphy SE et al. | β | 2005 | β |
| Nicotine metabolism in healthy smokers and patients with cardiovascular diseases. | Chahine R et al. | β | 2005 | β |
| Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. | Swan GE et al. | β | 2005 | β |
| Nicotine physical dependence and tolerance in the mouse following chronic oral administration. | Grabus SD et al. | β | 2005 | β |
| Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. | Anderson GD | β | 2005 | β |
| A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity. | Pitarque M et al. | β | 2004 | β |
| Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. | Kim K et al. | β | 2004 | β |
| Effects of cigarette smoking and exposure to cadmium and lead on phenotypic variability of hepatic CYP2A6 and renal function biomarkers in men. | Satarug S et al. | β | 2004 | β |
| Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. | Schoedel KA et al. | β | 2004 | β |
| Evidence for concurrent effects of exposure to environmental cadmium and lead on hepatic CYP2A6 phenotype and renal function biomarkers in nonsmokers. | Satarug S et al. | β | 2004 | β |
| Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers. | O'Loughlin J et al. | β | 2004 | β |
| Genetic polymorphism of the human cytochrome CYP2A13 in a French population: implication in lung cancer susceptibility. | Cauffiez C et al. | β | 2004 | β |
| Genetics and drug use as a complex phenotype. | Lessov CN et al. | β | 2004 | β |
| Genetics of tobacco use. | Maserejian NN et al. | β | 2004 | β |
| Identification of Val117 and Arg372 as critical amino acid residues for the activity difference between human CYP2A6 and CYP2A13 in coumarin 7-hydroxylation. | He XY et al. | β | 2004 | β |
| Nicotine, its metabolism and an overview of its biological effects. | Yildiz D | β | 2004 | β |
| Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6. | Denton TT et al. | β | 2004 | β |
| Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6). | von Richter O et al. | β | 2004 | β |
| Postnatal expression of cytochrome P450 1A1, 2A3, and 2B1 mRNA in neonatal rat lung: influence of maternal nicotine exposure. | Gamieldien K et al. | β | 2004 | β |
| Progress in searching for susceptibility loci and genes for smoking-related behaviour. | Li MD et al. | β | 2004 | β |
| Substrates of human cytochromes P450 from families CYP1 and CYP2: analysis of enzyme selectivity and metabolism. | Lewis DF et al. | β | 2004 | β |
| The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. | Miksys S et al. | β | 2004 | β |
| Watson and Crick 50 years on. From double helix to pharmacogenomics. | Sweeney BP | β | 2004 | β |
| Association of CYP2A6 gene deletion with cigarette smoking status in Japanese adults. | Ando M et al. | β | 2003 | β |
| Clinical considerations in study designs that use cotinine as a biomarker. | Bramer SL et al. | β | 2003 | β |
| Comparative American and Japanese tobacco smoke uptake parameters after overnight tobacco deprivation. | Domino EF et al. | β | 2003 | β |
| Decreasing smoking behaviour and risk through CYP2A6 inhibition. | Sellers EM et al. | β | 2003 | β |
| Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. | Schoedel KA et al. | β | 2003 | β |
| Environmental and genetic determinants of tobacco use: methodology for a multidisciplinary, longitudinal family-based investigation. | Swan GE et al. | β | 2003 | β |
| Genetic influences on smoking behavior and nicotine dependence: a review. | Yoshimasu K et al. | β | 2003 | β |
| Induction of nicotine-metabolizing CYP2B1 by ethanol and ethanol-metabolizing CYP2E1 by nicotine: summary and implications. | Schoedel KA et al. | β | 2003 | β |
| Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour. | Tricker AR | β | 2003 | β |
| The genetic determinants of smoking. | Batra V et al. | β | 2003 | β |
| Accelerated metabolism of nicotine and cotinine in pregnant smokers. | Dempsey D et al. | β | 2002 | β |
| An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. | Xu C et al. | β | 2002 | β |
| Clinical phenotyping strategies in selection of tobacco smokers for future genotyping studies. | Domino EF et al. | β | 2002 | β |
| CYP2A6 genetic variation and potential consequences. | Xu C et al. | β | 2002 | β |
| Gender differences in tobacco smoking: higher relative exposure to smoke than nicotine in women. | Zeman MV et al. | β | 2002 | β |
| Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant. | Zhang X et al. | β | 2002 | β |
| Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. | Tyndale RF et al. | β | 2002 | β |
| Molecular orbital calculations and nicotine metabolism: a rationale for experimentally observed metabolite ratios. | Lewis DF et al. | β | 2002 | β |
| Pharmacogenetic investigation of smoking cessation treatment. | Lerman C et al. | β | 2002 | β |
| The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence. | Howard LA et al. | β | 2002 | β |
| Tobacco smoking as a chronic disease: notes on prevention and treatment. | Batra V et al. | β | 2002 | β |
| A novel single nucleotide polymorphism altering stability and activity of CYP2a6. | Ariyoshi N et al. | β | 2001 | β |
| Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method. | Paschke T et al. | β | 2001 | β |
| Determination of coumarin metabolism in Turkish population. | Cok I et al. | β | 2001 | β |
| Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. | Tan W et al. | β | 2001 | β |
| Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. | Pitarque M et al. | β | 2001 | β |
| Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. | Schoedel KA et al. | β | 2001 | β |
| Polymorphisms of CYP2A6 and its practical consequences. | Raunio H et al. | β | 2001 | β |
| The use of gene knockout mice to unravel the mechanisms of toxicity and chemical carcinogenesis. | Gonzalez FJ | β | 2001 | β |
| Trans-3'-hydroxycotinine: disposition kinetics, effects and plasma levels during cigarette smoking. | Benowitz NL et al. | β | 2001 | β |
| 2'-Hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes: formation of a lung carcinogen precursor. | Hecht SS et al. | β | 2000 | β |
| CYP2D6 gene polymorphism in caucasian smokers: lung cancer susceptibility and phenotype-genotype relationships. | Laforest L et al. | β | 2000 | β |
| Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. | Rao Y et al. | β | 2000 | β |
| Functional variants at CYP2A6: new genotyping methods, population genetics, and relevance to studies of tobacco dependence. | Zabetian CP et al. | β | 2000 | β |
| Gender differences in addiction and recovery. | Haseltine FP | β | 2000 | β |
| Mimicking gene defects to treat drug dependence. | Sellers EM et al. | β | 2000 | β |
| Pronounced differences in inhibition potency of lactone and non-lactone compounds for mouse and human coumarin 7-hydroxylases (CYP2A5 and CYP2A6). | Juvonen RO et al. | β | 2000 | β |
| Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. | Miksys S et al. | β | 2000 | β |
| A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption. | Tyndale RF et al. | β | 1999 | β |
| A study of the psychometric and predictive properties of the FagerstrΓΆm Test for Nicotine Dependence in a population of young smokers. | Haddock CK et al. | β | 1999 | β |
| Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. | Oscarson M et al. | β | 1999 | β |
| Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. | Oscarson M et al. | β | 1999 | β |
| Nicotine metabolism variability and nicotine addiction. | Ahijevych K | β | 1999 | β |
| The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP. | Kitagawa K et al. | β | 1999 | β |
| Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. | Nowak MP et al. | β | 1998 | β |
| Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. | Oscarson M et al. | β | 1998 | β |
| Comparison of CYP2A6 catalytic activity on coumarin 7-hydroxylation in human and monkey liver microsomes. | Li Y et al. | β | 1997 | β |